German Reimbursement Dossiers Look Trickier After Rejection Of Eisai’s Fycompa
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai’s novel epilepsy drug Fycompa will have a tough time qualifying for reimbursement in Germany after the cost-effectiveness regulator IQWiG said the manufacturer did not stick to HTA guidance on comparator selection.